Phase 3 N=108 Safety Study of Entocort for Children With Crohn's Disease
Crohn's Disease
Primary: Adverse Event — 79 Patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=125 Study of Glasgow Coma Scale in Neurological Patients
Individuality
Primary: Interobserver Correlation — 98.9 percentage of correlation
N/A N=21 Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine
Fanconi Anemia
Primary: Incidence & Quality of Engraftment & Hematopoietic Reconstitution — 19 participants
Phase 2 N=98 Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Lymphoma
Primary: Progression Free Survival — 79 percentage of patients progression free
Phase 1 N=8 Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects
Healthy Subjects
Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio
Phase 2 N=10 Study of D-Methadone in Patients With Chronic Pain
Pain · Bladder Cancer · Breast Cancer
Primary: Number Who Reached a Safe Dose — 8 participants
Phase 2 N=40 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Hematologic and Organ Response — 11; 7; 18 participants
Phase 2 N=182 Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
Diabetic Neuropathy, Painful
Primary: Time to Efficacy Failure (TTEF) - Primary Responders — NA; NA Days
Phase 3 N=42 Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria
Arthritis, Reactive · Reiter Disease
Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01
N/A N=34 Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma
Melanoma
Primary: Toxicity — 1; 1; 6; 1 participants
Phase 2 N=27 Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes
MELAS Syndrome
Primary: Mean Change in Cerebral Lactate Concentration (as Measured by Magnetic Resonance Spectroscopy) — -0.09; 0.16; -0.49 IU
Phase 2 N=97 Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
Bladder Cancer
Primary: Treatment Completion Rate — 67; 53 percentage of participants
Phase 1 N=32 A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
Overactive Bladder
Primary: Area Under the Concentration-time Curve From 0 to Infinity (AUC0-∞) After a Single Oral Dose of Vibegron 100 mg — 6337.17; 7137.53; 5156.07; 3466.04 nM•hr
Phase 2 N=46 Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
Cancer of Head · Cancer of Head and Neck · Cancer of Neck
Primary: Probability of Progression-free Survival (PFS) at 2 Years — 70 percentage of participants
N/A N=7 Pilot Study for Automated Deep Brain Stimulation Programming
Parkinson's Disease · Tremor · Bradykinesia
Primary: Percent Change From Baseline in Kinesia HomeView Symptom Ratings After Guided DBS Programming — -35.7 Percentage change